Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $24.58 USD
Change Today +0.74 / 3.10%
Volume 280.8K
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

fibrogen inc (FGEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/6/15 - $40.59
52 Week Low
06/2/15 - $16.95
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for FIBROGEN INC (FGEN)

Related News

No related news articles were found.

fibrogen inc (FGEN) Related Businessweek News

No Related Businessweek News Found

fibrogen inc (FGEN) Details

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing roxadustat, or FG-4592, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; FG-3019, a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. The company also has a PHD1 inhibitor program, FG-8205 that is in preclinical evaluation for use as a cardioprotective agent to prevent the onset of heart failure following a heart attack; and FG-6874, an another novel HIF-PH inhibitor that has completed Phase I single dose and multiple dose studies for hematopoietic stem cell mobilization and certain other indications. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

348 Employees
Last Reported Date: 03/26/15
Founded in 1993

fibrogen inc (FGEN) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $736.6K
Chief Medical Officer
Total Annual Compensation: $443.5K
Vice President of Clinical Development
Total Annual Compensation: $428.7K
Compensation as of Fiscal Year 2014.

fibrogen inc (FGEN) Key Developments

FibroGen, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

FibroGen, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $120,550,000 against $89,958,000 a year ago. Income from operations was $59,315,000 against $49,173,000 a year ago. Income before income taxes was $57,260,000 against $46,831,000 a year ago. Net income was $57,055,000 or $0.83 per diluted share against $46,831,000 or $0.58 per diluted share a year ago. For the six months, the company reported total revenue of $136,848,000 against $107,834,000 a year ago. Income from operations was $14,592,000 against $34,967,000 a year ago. Income before income taxes was $10,622,000 against $30,591,000 a year ago. Net income was $10,688,000 or $0.15 per diluted share against $30,591,000 or $0.46 per diluted share a year ago.

FibroGen, Inc Reports Results of Nephrology Dialysis Transplantation Phase 2 Data

FibroGen, Inc. announced that Nephrology Dialysis Transplantation has published encouraging Phase 2a safety and efficacy data for roxadustat, an orally active potent hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of anemia associated with chronic kidney disease (CKD). In a multicenter, randomized, placebo-controlled trial that was conducted in non-dialysis subjects with anemia associated with stage 3 or 4 CKD, roxadustat produced dose-dependent increases in hemoglobin (Hb) within 14 to 25 days. Untreated or delayed treatment of CKD-associated anemia can be linked to a higher likelihood of hospitalization, red blood cell transfusion, and mortality rates. This study evaluated 116 subjects who were living with CKD and concomitant anemia but were not undergoing dialysis. Of these 116 subjects, 96 were evaluable for efficacy. Baseline characteristics for roxadustat and placebo groups were comparable. Roxadustat 0.7, 1.0, 1.5, or 2.0 mg/kg, increased Hb levels in a dose-related manner. Hb responder rates were dose dependent and ranged from 30% with roxadustat 0.7 mg/kg to 100% with roxadustat 2 mg/kg. The median time to response ranged from 42 days (1 mg/kg) to 14 days (2 mg/kg). Roxadustat transiently and moderately increased endogenous erythropoietin and reduced hepcidin levels. Adverse events were similar in the roxadustat and placebo groups. Most common adverse events associated with roxadustat were diarrhea (9.1%), headache (6.8%), back pain (4.5%), fatigue (4.5%) and hyperkalemia (4.5%).

FibroGen, Inc. to Report Q2, 2015 Results on Aug 13, 2015

FibroGen, Inc. announced that they will report Q2, 2015 results After-Market on Aug 13, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FGEN:US $24.58 USD +0.74

FGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FGEN.
View Industry Companies

Industry Analysis


Industry Average

Valuation FGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.8x
Price/Book 5.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FIBROGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at